Pharmacoeconomic analysis of the use of fulvestrant compared to chemotherapy for the treatment of patients with locally advanced or metastatic ER (+) HER2 (-) breast cancer

Abstract

In Ukraine, the use of fulvestrant, an estrogen receptor antagonist, is complicated by its high cost. Very often, when there are indications for its use, traditional chemotherapy regimens (HT) are used, most often the CMF regimen (cyclophosphamide + methotrexate + fluorouracil). The aim of the study. This study was a pharmacoeconomic evaluation of the use of fulvestrant (500 mg 1 r/month) compared to the CMF chemotherapy regimen (cyclophosphamide 600 mg/m2, methotrexate 40 mg/m2, fluorouracil 600 mg/m2) for the treatment of patients with locally progressive or metastatic ER (+) HER2 (–) breast cancer in postmenopausal women periods with relapse or progression of the disease after the use of the first line of hormonal therapy (anti- estrogens and aromatase inhibitors) and in the absence of a visceral crisis.